844-MY NK CELLScontact@nantkwest.com

      INVESTOR RELATIONS

      Overview

      We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
      NK (Common Stock) $7.860.00 (0.00%)
      Data provided by Nasdaq. Minimum 15 minutes delayed.

      Latest News

      NantKwest Expands NANT Cancer Vaccine Program With Additional Clinical Trials Announced Addressing Multiple Cancer Types Across All Stages of

      Jun 06, 2017 | Press Releases

      First Combination Off The Shelf NK And Adaptive Immunotherapy Trial To Be Initi

      Read More

      NantKwest to Present at the Jefferies Healthcare Conference on June 7, 2017

      Jun 02, 2017 | Press Releases

      CULVER CITY, Calif.--(BUSINESS WIRE)--Jun. 2, 2017-- NantKwest (Nasdaq:NK), a l

      Read More

      NantKwest Appoints Dr. John Lee as Senior Vice President of Adult Medical Affairs

      May 18, 2017 | Press Releases

      Company Adds Immuno-Oncology and Clinical Trial Expert to Leadership Team

      Read More

      Upcoming Events
      There are currently no events scheduled.
      Receive E-mail Alerts
      Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.